Report Store Get Proposal

Home Blog Infectious diseases

Infectious Diseases

pharma-news-for-incyte-gilead-archeus

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma; Gilead’s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte’s OPZELURA for Pediatric Atopic Dermatitis (Ages 2–11); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals’ HARLIKU Gets First FDA Approval for Alkaptonuria

Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular LymphomaIncyte has announced that the FDA has approved MONJUVI (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This makes it the first FDA-approved CD19- and CD20-targeted immunotherapy combination for this patient population. The approval is based on the pivotal Phase III inMIND trial, which showed a significant improvement in progression-free survival (PFS) with the MONJUVI regimen compared to the control arm. Patients receiving the combination therapy had a median PFS of 22.4 months...

Explore More...

pharma-news-for-celltrion-csl-ocugen

Celltrion Announces FDA Nod for New STEQEYMA Presentation to Broaden Pediatric Use; CSL’s ANDEMBRY Gets FDA Nod as First Factor XIIa Inhibitor for Hereditary Angioedema; Ocugen’s OCU410ST Cleared by FDA to Begin Phase II/III Trial in Stargardt Disease; Milestone Pharmaceuticals Submits FDA Response for CARDAMYST in PSVT; AbbVie’s MAVYRET Approved by FDA as First and Only Therapy for Acute Hepatitis C

ai-healthcare-startups-funding-trends

AI Healthcare Startups: Unveiling Investment and Funding Trends

pharma-news-for-amylyx-cellectar-merck

Amylyx’s AMX0114 Fast Tracked by FDA for ALS; Cellectar’s Iopofosine I 131 Granted FDA Breakthrough in Waldenstrom Macroglobulinemia; YolTech’s YOLT-101 Clears FDA IND for Familial Hypercholesterolemia; Oncovita’s MVdeltaC Gets FDA Orphan Tag for Pleural Mesothelioma; Merck’s ENFLONSIA Approved for RSV Prevention in Infants

Feature-AI-Driven Diagnostics_ Why are They the Next Big Thing in Healthcare

AI-Driven Diagnostics: Why are They the Next Big Thing in Healthcare?

pharma-news-for-telix-merck-alnylam

Clover’s SCB-1019 RSV Revaccination Study Clears U.S. IND; FDA Approves AMVUTTRA for ATTR-CM CV Risk Reduction; Pembrolizumab Combo Greenlit for HER2+ Gastric/GEJ Cancer; TREMFYA Becomes First IL-23 Inhibitor Approved for Crohn’s; FDA OKs GOZELLIX for Prostate Cancer Imaging

pharma-news-for-signet-bavarian-indivior

CTEXLI Approved for Cerebrotendinous Xanthomatosis; SIGX1094 Wins Fast Track for Diffuse Gastric Cancer; Bavarian Nordic’s Chikungunya Vaccine Cleared for Ages 12+; UX111 Gene Therapy Gains Priority Review for Sanfilippo Syndrome; SUBLOCADE Label Update Approved

pharma-news-for-galderma-gsk-astellas

EU Approves Galderma’s NEMLUVIO for Atopic Dermatitis and Prurigo Nodularis; GSK’s Penmenvy Wins FDA Nod; Ono Pharmaceuticals’ ROMVIMZA Gets Green Light from FDA for Symptomatic TGCT; Bristol Myers Squibb Updates on RELATIVITY-098 Phase III Trial Findings; FDA Expands Label for Astellas’ IZERVAY in Geographic Atrophy Treatment

parkinson's

Parkinson’s and Tuberculosis Share a Common Protein That Could Provide Better Drugs for Both

applications-of-biochips-in-healthcare

Biochips in Healthcare: 8 Groundbreaking Applications Shaping the Industry

orlynvah-for-uncomplicated-urinary-tract-infections

ORLYNVAH – The First Oral Penem in the US Market: A New Era in UTI Treatment

Widespread Usage of HPV Vaccine Reduces Cervical Cancers and Precancers

Pharma-news-for-modalis-pfizer-hibercell

FDA Grants Orphan Status to MDL-101 for LAMA2-CMD; Pfizer’s ABRYSVO Approved for High-Risk Adults (18-59); KIND’s AND017 Gains Orphan Designation for Sickle Cell Disease; HiberCell’s HC-7366 Fast-Tracked for AML; ORLYNVAH Approved for Uncomplicated UTIs

pharma-news-for-gilead-merck-astellas

Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025

helicobacter-pylori-infections-treatment

Helicobacter pylori Infections Treatment: Emerging Molecular Targets

Nonalcoholic steatohepatitis Treatment Landscape Which Pipeline Therapy Will Steal the Spotlight

Nonalcoholic Steatohepatitis Treatment Market: Which Pipeline Therapy Will Steal the Spotlight?

Pharma-news-for-merck-pfizer-novartis

Merck’s WINREVAIR™ EU Approval; BALVERSA for Urothelial Carcinoma; Novartis and Versant’s Borealis Launched; Moderna’s RSV mRESVIA® EU Approval; FDA Nods RYBREVANT® and LAZCLUZE™ for EGFR-mutated Lung Cancer